当天，仁济医院还发布了AI智能外科培训、急危重症模拟训练等四大国际培训项目，打造"理论+实操 +模拟"的立体化教育体系，吸引全球医学生来华学习交流，推动中国医疗智慧与世界共享。 复旦大学附属中山医院(中山医院)方面介绍，参展WHX2026是医院综合实力的自信展示，也体现了医 院寻求广泛深入国际合作的积极姿态。该院重点分享肝脏外科、心血管疾病等传统优势学科的成熟诊疗 上海交通大学医学院附属仁济医院(简称：仁济医院)以"智慧医院整体方案"为核心，携6项重磅智慧医 疗成果亮相展览，向世界展示了中国上海在医疗健康领域的创新实力与开放姿态。 9日当天，在中国工程院院士、仁济医院院长夏强的带领下，"仁济智慧医院整体方案V1.0"全球首发。 方案涵盖了智慧手术部、智慧ICU、智慧病房和互联网医院平台等多个场景，完整勾勒出"以患者为中 心、以AI为驱动"的未来医院新范式。方案一经发布，便迅速吸引了中东、欧洲、东南亚等地区国家医 疗同行的高度关注。夏强表示，医疗出海不只是救治，更是技术共享与生命接力。 据悉，仁济医院展台上的"AI医生助理(AI Doctor Assistant, AIDA)"引来众多现场观众。据介绍，它并非 ...

Core Insights - The article highlights the emergence of AI technologies in the pharmaceutical and medical fields, particularly focusing on the advancements made by Chinese AI company DeepSeek and its large model R1, which has gained recognition in the scientific community [2] - The integration of AI in drug discovery and clinical applications is accelerating, with significant investments from major pharmaceutical companies aiming to revolutionize the drug development process [4][5] Group 1: AI in Drug Discovery - Major pharmaceutical companies, including Bristol-Myers Squibb and Sanofi, are investing billions in AI drug discovery, hoping to achieve breakthroughs that will transform the drug development process [4] - Medidata's data indicates that the proportion of clinical trials initiated by Chinese companies has surged from approximately 3% to 30% by 2024, positioning China as the second-largest clinical trial market globally [4] - AI is expected to drive a new wave of drug development, becoming a crucial force in the transformation of new drug research [4] Group 2: AI in Medical Applications - The "Meta-Medical" laboratory, launched by Zhongshan Hospital affiliated with Fudan University, aims to develop AI agents and apply large model technologies to enhance medical knowledge digitization and productization of diagnostic capabilities [6] - AI is changing the paradigm of diagnosis and treatment, with significant advancements in areas such as heart disease risk prediction and real-time monitoring through wearable devices [6] - The successful application of AI in specific medical fields has reached clinical levels, exemplified by the monitoring of intermittent atrial fibrillation using wearable technology [6] Group 3: Challenges and Ethical Considerations - Despite the potential of AI in drug discovery, challenges remain, including a 90% failure rate in clinical trials and the need to address complex biological issues and regulatory hurdles [5] - Ethical considerations are paramount, with the responsibility for medical decisions still resting with physicians, who must ensure that AI technologies are used safely and effectively in clinical settings [7]

Core Insights - The "Meta Medical Simulation Laboratory" has been established through collaboration between Fudan University Zhongshan Hospital, Huawei Technologies Co., Ltd., and Shanghai United Imaging Healthcare Co., Ltd. [1] - The laboratory aims to create a positive feedback loop system that encompasses clinical demand identification, technological research and development, product iteration optimization, and application promotion feedback in the context of AI-driven meta medicine [1] Company Collaboration - Fudan University Zhongshan Hospital, Huawei Technologies Co., Ltd., and Shanghai United Imaging Healthcare Co., Ltd. are the key players involved in the establishment of the laboratory [1] - This collaboration signifies a strategic partnership aimed at advancing medical technology and innovation [1] Technological Innovation - The laboratory is designed to leverage innovative concepts and technologies in the AI era, focusing on enhancing medical practices and patient care [1] - It emphasizes the importance of integrating clinical needs with technological advancements to improve healthcare outcomes [1]